TABLE 1.
Characteristics of the included studies.
| Citation (first author et al., year) | Location | Study population | Sample size | Mean age | Q10 dosage (mg) | Duration (Week) | Main outcome |
|---|---|---|---|---|---|---|---|
| Zhai et al. (2017) | China | NAFLD, MS, CAD, MI | 180 | 46.9 | 275 | 12 | IL-6 ↔ |
| risk of CVD in CKD, obesity, CAD, NAFLD, MetS, HTN | 331 | 52.2 | 185.7 | 10 | CRP ↔ | ||
| NAFLD, MS, CAD | 128 | 43.5 | 300 | 12 | TNF-α↓ | ||
| Fan et al. (2017) | China | runners, NAFLD, CAD, mild hypertensive, RA, renal lithiasis, hyperlipidemic with MI, MS | 402 | 45.5 | 201.1 | 9 | IL-6↓ |
| runners, NAFLD, CAD, end stage heart failure, RA, MS | 217 | 43.6 | 194.8 | 9.5 | TNF-α ↓ | ||
| systolic dysfunction, runners, T2DM, NAFLD, obese, CAD, hypercholesterolemia, chronic renal impairment, mild hypertensive, heart failure, ESRD | 543 | 53.4 | 159 | 11 | CRP ↓ | ||
| Mazidi et al. (2018) | China | ischemic LVSD, DM with neuropathy, BMI>25, CAD | 385 | 65.9 | 188.75 | 11 | IL-6↓ |
| stenosis of one major, coronary artery, chronic renal impairment, mildly hypertensive | CRP↔ | ||||||
| Jorat et al. (2019) | Iran | CAD, AMI, MI | 295 | 54.4 | 114 | 13 | MDA↓ |
| CHF, end stage heart failure, CAD | 102 | 66 | 170 | 20 | TNF-α ↔ | ||
| CAD, T2DM with coronary heart disease | 155 | 68.3 | 152.5 | 11 | IL-6 ↔ | ||
| CAD, systolic dysfunction, CHF, ischemic heart disease | 313 | 63.6 | 218.3 | 10.5 | CRP↔ | ||
| CAD, ischemic heart disease, systolic dysfunction | 184 | 67.9 | 222 | 10 | SOD↑ | ||
| Zhang et al. (2019) | China | CKD | 115 | 67.2 | 65 | 12 | MDA↓ |
| Farsi et al. (2019) | Iran | migraine, HCC, NAFLD, RA, mild HTN, MS, CAD, end-stage heart failure | 348 | 48.7 | 232.5 | 11.5 | TNF-α ↔ |
| migraine, HCC, T2DM, NAFLD, RA, mild HTN, MS, HLP with MI, CAD | 454 | 55.9 | 210 | 11 | IL-6 ↓ | ||
| HCC, NAFLD, mild HTN, CAD | 208 | 65.4 | 168.3 | 12 | CRP ↔ | ||
| Dludla et al. (2020) | South Africa | mildly hypertensive, NAFLD | 101 | NR | 100 | 12 | TNF-α↔ |
| CRP ↓ | |||||||
| NAFLD, T2DM | 161 | 47.5 | 366.6 | 6.5 | MDA↔ | ||
| Akbari et al. (2020) | Iran | HD, T2DM, T1DM, bipolar disorders, acute coronary syndrome, RA, NAFLD | 540 | 48.8 | 114 | 11.5 | MDA ↓ |
| bipolar disorders, HD, T2DM, RA, NAFLD | 464 | 52.8 | 165 | 11 | TAC↑ | ||
| Hepatocellular carcinoma, renal injury, CAD, systolic dysfunction | 237 | 62.2 | 275 | 8 | SOD↑ | ||
| Sangsefidi et al. (2020) | Iran | T2D, ESRF, healthy, CRF, DN, HCC, MS, CAD, RA, NAFLD | 715 | NR | 182.1 | 11 | MDA↓ |
| NAFLD, RA, MS, dyslipidemia, T2DM | 481 | NR | 167.4 | 12 | TAC↑ | ||
| ischemic LVSD, CAD, MS, HCC, T2DM | 284 | NR | 244.2 | 11.5 | SOD↑ | ||
| Hajiluian et al. (2021) | Iran | RA, kidney disease, NAFLD, T2DM, CVD | 480 | 53.9 | 104.4 | 11 | MDA ↓ |
| T2DM | 236 | 57.2 | 100 | 10 | MDA ↓ | ||
| RA, kidney disease, NAFLD, CVD | 244 | 50.6 | 108 | 12 | MDA↓ | ||
| RA, T2DM, kidney disease, NAFLD | 406 | 54.8 | 160 | 11.5 | TAC↑ | ||
| RA, NAFLD, kidney disease | 148 | 51.3 | 106.6 | 8 | TAC↔ | ||
| T2DM | 258 | 57.5 | 200 | 14 | TAC↑ | ||
| kidney disease, CVD, cancer | 248 | 62.2 | 275 | 8.5 | SOD↑ | ||
| Alimohammadi et al. (2021) | Iran | breast cancer | 156 | 57 | 100 | 9.5 | SOD↑ |
| TNF-α↓ | |||||||
| IL-6↓ | |||||||
| Dai et al. (2022) | China | Healthy, dyslipidemia, NAFLD, T2DM, hepatocellular carcinoma, coronary artery disease, bipolar disorder, MS, hemodialysis | 1912 | 50 | 200 | 11.5 | MDA ↓ |
| TAC↑ | |||||||
| SOD↔ | |||||||
| Sedaghat et al. (2022) | Iran | Healthy, dyslipidemia, NAFLD, T2DM, hepatocellular carcinoma, coronary artery disease, bipolar disorder, MS, renal injury, ICU patients, autism, migraine | 1,267 | NR | 195 | 9 | MDA ↓ |
| TAC↑ | |||||||
| SOD↑ |
Abbreviations: NR, not reported; NAFLD, nonalcoholic fatty liver disease; MS, multiple sclerosis; CAD, coronary artery disease; MI, myocardial infarction; MetS, metabolic syndrome; HTN, hypertension; RA, rheumatoid arthritis; T2DM, Type 2 diabetes; CVD, cardiovascular disease; ESRD, End-Stage Renal Disease; LVSD, Left Ventricular Systolic Dysfunction; HCC, hepatocellular carcinoma; DN, diabetic nephropathy; AMI, acute myocardial infarction.